CN109692176A - A kind of piperazine ferulate pharmaceutical preparation - Google Patents
A kind of piperazine ferulate pharmaceutical preparation Download PDFInfo
- Publication number
- CN109692176A CN109692176A CN201710990673.XA CN201710990673A CN109692176A CN 109692176 A CN109692176 A CN 109692176A CN 201710990673 A CN201710990673 A CN 201710990673A CN 109692176 A CN109692176 A CN 109692176A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical preparation
- piperazine ferulate
- adhesive
- filler
- disintegrating agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 25
- OEWLZTGXBCJPKL-MSEGBBJSSA-N (e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid;piperazine Chemical compound C1CNCCN1.COC1=CC(\C=C\C(O)=O)=CC=C1O.COC1=CC(\C=C\C(O)=O)=CC=C1O OEWLZTGXBCJPKL-MSEGBBJSSA-N 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 22
- 239000000853 adhesive Substances 0.000 claims description 16
- 230000001070 adhesive effect Effects 0.000 claims description 16
- 239000002075 main ingredient Substances 0.000 claims description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- 235000020985 whole grains Nutrition 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000005550 wet granulation Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000001035 drying Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of piperazine ferulate pharmaceutical preparations, it is characterised in that the pharmaceutical preparation is made of 20-30% piperazine ferulate and the pharmaceutically acceptable auxiliary material of 70-80%.Piperazine ferulate pharmaceutical preparation preparation process of the present invention is simple, lower production costs, is conducive to industrialized production.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, and in particular to a kind of piperazine ferulate pharmaceutical preparation.
Background technique
Piperazine Ferulate Tablets, indication are that this product is suitable for all kinds of glomerulus diseases with microscopic hematuria and hypercoagulative state
Disease, such as ephritis, chronic nephritis, nephrotic syndrome, early stage uremia and coronary heart disease, cerebral infarction, vasculitis adjuvant treatment.
But its preparation process has no its pertinent literature report and patent protection.
Summary of the invention
The present invention is intended to provide a kind of prescription science, the simple piperazine ferulate pharmaceutical preparation of preparation process.
For achieving the above object, technical solution of the present invention are as follows:
A kind of piperazine ferulate pharmaceutical preparation of the present invention, the pharmaceutical preparation is by 20-30% piperazine ferulate and 70-80% drug
Upper acceptable auxiliary material composition.
A kind of piperazine ferulate pharmaceutical preparation of the present invention, the pharmaceutical preparation pharmaceutic adjuvant include disintegrating agent, filler,
Adhesive, lubricant.
A kind of piperazine ferulate pharmaceutical preparation of the present invention, the pharmaceutical preparation auxiliary material weight percent are as follows: disintegrating agent 51-
70%, filler 5-10%, adhesive 0.5%-5%, lubricant 5%-8%.
Specifically prescription each component percentage of the present invention are as follows:
A kind of piperazine ferulate pharmaceutical preparation of the present invention, it is characterised in that the pharmaceutical preparation is the preparation method comprises the following steps: by main ingredient, form sediment
Powder, disintegrating agent, filler, adhesive, magnesium stearate cross 80 meshes respectively, weigh respectively in proportion, wherein (1) main ingredient and hard
Fatty acid magnesium sieving, equivalent gradually-increased mix；(2) starch, disintegrating agent, filler sieving mix, and adhesive wet granulation is added,
Drying, whole grain；Pellet through sieves made from mixture made from step (1) and step (2) are mixed, tabletting.
The invention has the advantages that: piperazine ferulate pharmaceutical preparation preparation process of the present invention is simple, lower production costs are conducive to
Industrialized production.
Specific embodiment
Following example is only to further illustrate the present invention, range that the invention is not limited in any way.
Embodiment 1
Preparation process: (a) being the powder part containing main ingredient and magnesium stearate.By main ingredient and magnesium stearate, 80 meshes are crossed respectively, are pressed
Proportion weighs, and equivalent is progressively increased uniformly mixed；(b) starch, crosslinked polyvinylpyrrolidone, lactose cross 80 meshes, weigh according to the ratio,
It is uniformly mixed, prepares 10% adhesive, adhesive, the granulation of 16 meshes, drying, 24 mesh whole grains are added.(a) and (b) two parts
Equivalent gradually-increased is uniformly mixed, tabletting.
Embodiment 2
Preparation process: (a) being the powder part containing main ingredient and magnesium stearate.By main ingredient and magnesium stearate, 80 meshes are crossed respectively, are pressed
Proportion weighs, and equivalent is progressively increased uniformly mixed；(b) starch, low-substituted hydroxypropyl cellulose, mannitol cross 80 meshes, claim according to the ratio
Amount is uniformly mixed, and prepares 10% adhesive, and adhesive, the granulation of 16 meshes, drying, 24 mesh whole grains are added.(a) and (b) two
Divide equivalent gradually-increased, is uniformly mixed, tabletting.
Embodiment 3
Preparation process: (a) being the powder part containing main ingredient and magnesium stearate.By main ingredient and magnesium stearate, 80 meshes are crossed respectively, are pressed
Proportion weighs, and equivalent is progressively increased uniformly mixed；(b) starch, microcrystalline cellulose, mannitol cross 80 meshes, weigh according to the ratio, and mixing is equal
It is even, 10% adhesive is prepared, adhesive, the granulation of 16 meshes, drying, 24 mesh whole grains are added.(a) it is passed with (b) two parts equivalent
Addition is uniformly mixed, tabletting.
Embodiment 4
Preparation process: (a) being the powder part containing main ingredient and magnesium stearate.By main ingredient and magnesium stearate, 80 meshes are crossed respectively, are pressed
Proportion weighs, and equivalent is progressively increased uniformly mixed；(b) starch, microcrystalline cellulose, mannitol cross 80 meshes, weigh according to the ratio, and mixing is equal
It is even, 10% adhesive is prepared, adhesive, the granulation of 16 meshes, drying, 24 mesh whole grains are added.(a) it is passed with (b) two parts equivalent
Addition is uniformly mixed, tabletting.
Claims (4)
1. a kind of piperazine ferulate pharmaceutical preparation, it is characterised in that the pharmaceutical preparation is by 20-30% piperazine ferulate and 70-80% medicine
Acceptable auxiliary material composition on object.
2. a kind of piperazine ferulate pharmaceutical preparation according to claim 1, it is characterised in that the pharmaceutical preparation pharmaceutic adjuvant packet
Include disintegrating agent, filler, adhesive, lubricant.
3. a kind of piperazine ferulate pharmaceutical preparation according to claim 1, it is characterised in that the pharmaceutical preparation auxiliary material weight hundred
Divide ratio are as follows: disintegrating agent 51-70%, filler 5-10%, adhesive 0.5%-5%, lubricant 5%-8%.
4. any one of -3 a kind of piperazine ferulate pharmaceutical preparation according to claim 1, it is characterised in that the pharmaceutical preparation system
Preparation Method are as follows: main ingredient, starch, disintegrating agent, filler, adhesive, magnesium stearate are crossed into 80 meshes respectively, claimed respectively in proportion
It takes, wherein (1) main ingredient and Magnesium Stearate, equivalent gradually-increased mix；(2) starch, disintegrating agent, filler sieving mix, and add
Enter adhesive wet granulation, dries, whole grain；Pellet through sieves made from mixture made from step (1) and step (2) are mixed,
Tabletting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710990673.XA CN109692176A (en) | 2017-10-23 | 2017-10-23 | A kind of piperazine ferulate pharmaceutical preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710990673.XA CN109692176A (en) | 2017-10-23 | 2017-10-23 | A kind of piperazine ferulate pharmaceutical preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109692176A true CN109692176A (en) | 2019-04-30 |
Family
ID=66225780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710990673.XA Pending CN109692176A (en) | 2017-10-23 | 2017-10-23 | A kind of piperazine ferulate pharmaceutical preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109692176A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1433761A (en) * | 2003-02-21 | 2003-08-06 | 李红洁 | Piperazine ferulate slow-released, control-released agent |
| CN1742726A (en) * | 2005-09-23 | 2006-03-08 | 北京阜康仁生物制药科技有限公司 | Piperazine ferulate oral cavity disintegrating tablet and preparing method |
| CN101555235A (en) * | 2009-05-20 | 2009-10-14 | 湖南康普制药有限公司 | Manufacture process of piperazine ferulate |
| CN102335153A (en) * | 2010-07-16 | 2012-02-01 | 浙江九洲药物科技有限公司 | Piperazine ferulate sustained-release tablet and its preparation method |
-
2017
- 2017-10-23 CN CN201710990673.XA patent/CN109692176A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1433761A (en) * | 2003-02-21 | 2003-08-06 | 李红洁 | Piperazine ferulate slow-released, control-released agent |
| CN1742726A (en) * | 2005-09-23 | 2006-03-08 | 北京阜康仁生物制药科技有限公司 | Piperazine ferulate oral cavity disintegrating tablet and preparing method |
| CN101555235A (en) * | 2009-05-20 | 2009-10-14 | 湖南康普制药有限公司 | Manufacture process of piperazine ferulate |
| CN102335153A (en) * | 2010-07-16 | 2012-02-01 | 浙江九洲药物科技有限公司 | Piperazine ferulate sustained-release tablet and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110403911A (en) | A kind of isosorbide mononitrate sustained release tablets and preparation method thereof | |
| US8703187B2 (en) | Vitamin D content uniformity in pharmaceutical dosage forms | |
| CN102114005B (en) | Tracleer capsule and preparation method thereof | |
| CN106667936B (en) | Sofosbuvir tablet and preparation method thereof | |
| CN107753455B (en) | A tablet containing imidafenacin and its preparation method | |
| CN104107173A (en) | Roflumilast tablet and preparation method thereof | |
| CN102144983A (en) | Entecavir dispersible tablets and preparation method thereof | |
| CN104940160B9 (en) | Improved Oseltamivir phosphate solid composite and preparation method thereof | |
| CN102871977A (en) | Ulipristal acetate dispersible tablet and preparation method thereof | |
| CN109692176A (en) | A kind of piperazine ferulate pharmaceutical preparation | |
| CN102626410A (en) | Pharmaceutical composition containing roflumilast | |
| CN103083326A (en) | Ulipristal acetate medicine composition | |
| CN102144984A (en) | Easy-dissolution lamivudine tablet and preparation method thereof | |
| CN107684549A (en) | A kind of Valsartan tablet and preparation method thereof | |
| CN103356495A (en) | Letrozole tablet and preparation method thereof | |
| CN104382873B (en) | A kind of mycophenolate mofetil dispersible tablet | |
| CN103405394A (en) | Metoprolol tartrate sustained release tablet and preparation method thereof | |
| CN106539766A (en) | Glug arranges net tablet and preparation method thereof | |
| CN102988372A (en) | Screening and composition of main auxiliary materials of compound aspirin tablet, and preparation method of compound aspirin sheet | |
| CN105769779A (en) | Acyclovir dispersible tablet and preparation method thereof | |
| CN113768889B (en) | Cilostazol-containing pharmaceutical composition and preparation method thereof | |
| CN102349882A (en) | Medicinal composition containing trandolapril and preparation process thereof | |
| CN103142533A (en) | Enteric coated tablet of etoposide | |
| CN102988320B (en) | Capecitabine dispersible tablet and preparation method thereof | |
| Amol et al. | Formulation of lisinopril dihydrate tablet and study effect of extent of granulation on response variables |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190430 |